Korea Investment CORP Acquires 22,100 Shares of Hologic, Inc. (NASDAQ:HOLX)

Korea Investment CORP lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 18.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,831 shares of the medical equipment provider’s stock after acquiring an additional 22,100 shares during the period. Korea Investment CORP owned approximately 0.06% of Hologic worth $10,080,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Benson Investment Management Company Inc. bought a new position in Hologic in the 4th quarter worth about $4,832,000. Principal Financial Group Inc. lifted its holdings in shares of Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after buying an additional 1,606 shares in the last quarter. Clean Yield Group boosted its position in shares of Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after acquiring an additional 7,266 shares during the period. Janus Henderson Group PLC grew its stake in Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after acquiring an additional 800 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after acquiring an additional 238,222 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Raymond James restated an “outperform” rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. BNP Paribas raised Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Royal Bank of Canada lowered their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Up 0.7 %

Shares of HOLX opened at $61.77 on Tuesday. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The firm has a market cap of $13.86 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 2.14 and a beta of 0.97. The firm has a 50 day moving average price of $65.08 and a 200-day moving average price of $73.11. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.